FEATURED COMPANIES
- Alexza Pharmaceuticals
- Bausch Health
- Neurelis
- Pfizer Inc.
- Sanofi
- UCB S.A.
Global Acute Repetitive Seizures Market to Reach $5.2 Billion by 2027
Amid the COVID-19 crisis, the global market for Acute Repetitive Seizures estimated at US$437.3 Million in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2027, growing at a CAGR of 42.4% over the analysis period 2020-2027. Diastat Rectal Gel, one of the segments analyzed in the report, is projected to record a 44.5% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the USL-261 segment is readjusted to a revised 37.3% CAGR for the next 7-year period.
![Global Market for Acute Repetitive Seizures]( "Global Market for Acute Repetitive Seizures")
The U.S. Market is Estimated at $117.2 Million, While China is Forecast to Grow at 49.7% CAGR
The Acute Repetitive Seizures market in the U.S. is estimated at US$117.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 49.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 35.2% and 39.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 37.8% CAGR.
NRL-1 Segment to Record 45% CAGR
In the global NRL-1 segment, USA, Canada, Japan, China and Europe will drive the 43.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$66.5 Million in the year 2020 will reach a projected size of US$840.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$797 Million by the year 2027, while Latin America will expand at a 47.2% CAGR through the analysis period.
Select Competitors (Total 36 Featured):
Amid the COVID-19 crisis, the global market for Acute Repetitive Seizures estimated at US$437.3 Million in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2027, growing at a CAGR of 42.4% over the analysis period 2020-2027. Diastat Rectal Gel, one of the segments analyzed in the report, is projected to record a 44.5% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the USL-261 segment is readjusted to a revised 37.3% CAGR for the next 7-year period.
The U.S. Market is Estimated at $117.2 Million, While China is Forecast to Grow at 49.7% CAGR
The Acute Repetitive Seizures market in the U.S. is estimated at US$117.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 49.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 35.2% and 39.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 37.8% CAGR.
NRL-1 Segment to Record 45% CAGR
In the global NRL-1 segment, USA, Canada, Japan, China and Europe will drive the 43.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$66.5 Million in the year 2020 will reach a projected size of US$840.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$797 Million by the year 2027, while Latin America will expand at a 47.2% CAGR through the analysis period.
Select Competitors (Total 36 Featured):
- Alexza Pharmaceuticals
- Bausch Health
- Neurelis
- Pfizer Inc.
- Sanofi
- UCB S.A.
- Valeant Pharmaceuticals North America LLC.
- Veriton Pharma
Frequently Asked Questions about the Global Market for Acute Repetitive Seizures
What is the estimated value of the Global Market for Acute Repetitive Seizures?
The Global Market for Acute Repetitive Seizures was estimated to be valued at $437.3 Million in 2020.
What is the growth rate of the Global Market for Acute Repetitive Seizures?
The growth rate of the Global Market for Acute Repetitive Seizures is 42.4%, with an estimated value of $5200.0 Million by 2027.
What is the forecasted size of the Global Market for Acute Repetitive Seizures?
The Global Market for Acute Repetitive Seizures is estimated to be worth $5200.0 Million by 2027.
Who are the key companies in the Global Market for Acute Repetitive Seizures?
Key companies in the Global Market for Acute Repetitive Seizures include Alexza Pharmaceuticals, Bausch Health, Neurelis, Pfizer Inc., Sanofi, UCB S.A. and Veriton Pharma.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Alexza Pharmaceuticals
- Bausch Health
- Neurelis
- Pfizer Inc.
- Sanofi
- UCB S.A.
I. METHODOLOGYII. EXECUTIVE SUMMARY
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Current & Future Analysis for Acute Repetitive Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 2: World Historic Review for Acute Repetitive Seizures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 3: World 15-Year Perspective for Acute Repetitive Seizures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
- Table 4: World Current & Future Analysis for Diastat Rectal Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 5: World Historic Review for Diastat Rectal Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 6: World 15-Year Perspective for Diastat Rectal Gel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- Table 7: World Current & Future Analysis for USL-261 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 8: World Historic Review for USL-261 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 9: World 15-Year Perspective for USL-261 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- Table 10: World Current & Future Analysis for NRL-1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 11: World Historic Review for NRL-1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 12: World 15-Year Perspective for NRL-1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- Table 13: World Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 14: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 15: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
- UNITED STATES
- Table 16: USA Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 17: USA Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 18: USA 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- CANADA
- Table 19: Canada Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 20: Canada Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 21: Canada 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- JAPAN
- Table 22: Japan Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 23: Japan Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 24: Japan 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- CHINA
- Table 25: China Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 26: China Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 27: China 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- EUROPE
- Table 28: Europe Current & Future Analysis for Acute Repetitive Seizures by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 29: Europe Historic Review for Acute Repetitive Seizures by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 30: Europe 15-Year Perspective for Acute Repetitive Seizures by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
- Table 31: Europe Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 32: Europe Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 33: Europe 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- FRANCE
- Table 34: France Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 35: France Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 36: France 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- GERMANY
- Table 37: Germany Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 38: Germany Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 39: Germany 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- ITALY
- Table 40: Italy Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 41: Italy Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 42: Italy 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- UNITED KINGDOM
- Table 43: UK Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 44: UK Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 45: UK 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- SPAIN
- Table 46: Spain Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 47: Spain Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 48: Spain 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- RUSSIA
- Table 49: Russia Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 50: Russia Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 51: Russia 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- REST OF EUROPE
- Table 52: Rest of Europe Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 53: Rest of Europe Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 54: Rest of Europe 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- ASIA-PACIFIC
- Table 55: Asia-Pacific Current & Future Analysis for Acute Repetitive Seizures by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 56: Asia-Pacific Historic Review for Acute Repetitive Seizures by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 57: Asia-Pacific 15-Year Perspective for Acute Repetitive Seizures by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
- Table 58: Asia-Pacific Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 59: Asia-Pacific Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 60: Asia-Pacific 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- AUSTRALIA
- Table 61: Australia Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 62: Australia Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 63: Australia 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- INDIA
- Table 64: India Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 65: India Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 66: India 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- SOUTH KOREA
- Table 67: South Korea Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 68: South Korea Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 69: South Korea 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- REST OF ASIA-PACIFIC
- Table 70: Rest of Asia-Pacific Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 71: Rest of Asia-Pacific Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 72: Rest of Asia-Pacific 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- LATIN AMERICA
- Table 73: Latin America Current & Future Analysis for Acute Repetitive Seizures by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 74: Latin America Historic Review for Acute Repetitive Seizures by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 75: Latin America 15-Year Perspective for Acute Repetitive Seizures by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
- Table 76: Latin America Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 77: Latin America Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 78: Latin America 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- ARGENTINA
- Table 79: Argentina Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 80: Argentina Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 81: Argentina 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- BRAZIL
- Table 82: Brazil Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 83: Brazil Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 84: Brazil 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- MEXICO
- Table 85: Mexico Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 86: Mexico Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 87: Mexico 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- REST OF LATIN AMERICA
- Table 88: Rest of Latin America Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 89: Rest of Latin America Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 90: Rest of Latin America 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- MIDDLE EAST
- Table 91: Middle East Current & Future Analysis for Acute Repetitive Seizures by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- Table 92: Middle East Historic Review for Acute Repetitive Seizures by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 93: Middle East 15-Year Perspective for Acute Repetitive Seizures by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
- Table 94: Middle East Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 95: Middle East Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 96: Middle East 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- IRAN
- Table 97: Iran Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 98: Iran Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 99: Iran 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- ISRAEL
- Table 100: Israel Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 101: Israel Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 102: Israel 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- SAUDI ARABIA
- Table 103: Saudi Arabia Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 104: Saudi Arabia Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 105: Saudi Arabia 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- UNITED ARAB EMIRATES
- Table 106: UAE Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 107: UAE Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 108: UAE 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- REST OF MIDDLE EAST
- Table 109: Rest of Middle East Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 110: Rest of Middle East Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 111: Rest of Middle East 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
- AFRICA
- Table 112: Africa Current & Future Analysis for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- Table 113: Africa Historic Review for Acute Repetitive Seizures by Product - Diastat Rectal Gel, USL-261, NRL-1 and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- Table 114: Africa 15-Year Perspective for Acute Repetitive Seizures by Product - Percentage Breakdown of Value Sales for Diastat Rectal Gel, USL-261, NRL-1 and Other Products for the Years 2012, 2020 & 2027
IV. COMPETITION
- Total Companies Profiled: 36
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Alexza Pharmaceuticals
- Bausch Health
- Neurelis
- Pfizer Inc.
- Sanofi
- UCB S.A.
- Valeant Pharmaceuticals North America LLC.
- Veriton Pharma
Note: Product cover images may vary from those shown
